Glaucoma Basics: Risk, Detection, and Protecting Vision

Glaucoma is often summarized as “high pressure in the eye,” but that shortcut is incomplete. It is a group of diseases in which the optic nerve is damaged in a characteristic pattern. Intraocular pressure is the most important modifiable risk factor, yet it is neither necessary nor sufficient for diagnosis.

That distinction prevents two errors. Do not assume inevitable blindness from one high pressure reading. Do not assume your optic nerve is safe because a pressure sits in the usual statistical range. Risk assessment combines history, anatomy, and pressure. It combines optic-nerve structure, visual function, and change over time.

The optic nerve is the focus#

The optic nerve carries visual information from retinal ganglion cells to the brain. Glaucoma damages those cells and their nerve fibers. Open-angle glaucoma, the most common U.S. type, usually changes slowly. Early central acuity may remain good while blind spots develop in the peripheral field. Your brain and your other eye can mask gradual loss, so symptoms are a poor early detector.

Angle-closure glaucoma involves blockage of the drainage angle between the iris and cornea. It can occur suddenly with a rapid pressure rise or more gradually. Acute angle closure may cause intense pain, red eye, and blur or halos. It may cause headache, nausea, and vomiting. NEI advises immediate emergency care for this pattern.

Other forms include congenital, secondary, normal-tension, pigmentary, and exfoliation glaucoma. The cause, anatomy, rate, and treatment differ. “Glaucoma” on a problem list should therefore be accompanied by type, severity, laterality, target, and follow-up plan when known.

Pressure is one piece of a multidimensional diagnosis#

Fluid is continuously produced and drained in the front of the eye. Resistance to outflow can raise intraocular pressure. Pressure varies across the day and measurements are influenced by technique and corneal thickness or biomechanics.

Some people have ocular hypertension, meaning pressure above a reference range without detectable glaucomatous nerve or field damage. Others have normal-tension glaucoma, in which characteristic damage occurs despite readings not considered elevated. There is no universal number that divides safe from unsafe for every optic nerve.

A glaucoma evaluation may include:

• repeat pressure measurement rather than reliance on one reading;
• gonioscopy to inspect whether the drainage angle is open or narrow;
• dilated examination and photography or imaging of the optic nerve and retinal nerve-fiber layers;
• standard automated visual-field testing;
• corneal-thickness measurement and relevant ocular anatomy;
• family, medical, medicine, injury, and surgical history;
• comparison with prior structure, fields, and pressures.

Optical coherence tomography can quantify tissue layers, but an image color code is not a diagnosis. Anatomy varies, artifacts occur, and early structural and functional tests may disagree. Repeating a reliable test and looking for a coherent pattern is often more informative than reacting to a single borderline result.

Risk is not destiny#

NEI identifies older age, a family history, and particular population patterns among important risk markers. In the United States, glaucoma burden and earlier presentation are higher among Black people, while risk rises in Hispanic or Latino populations with age. High eye pressure, a thin central cornea, and certain optic-nerve features may also matter. So may high myopia, prior eye injury, and some medical or ocular conditions.

Race and ethnicity are social and imperfect proxies, not biological diagnoses. They may capture ancestry, access, environmental conditions, and structural differences as well as unmeasured factors. Use them to recognize observed inequities and improve access, not to replace an individual examination.

Family history is more useful when specific: which relative, what type, at what age, whether vision was lost, and whether surgery was needed. A severe case in a close relative can change concern even if you have no symptom.

What “screening” evidence actually says#

The 2022 USPSTF recommendation applies to asymptomatic adults age 40 and older without known glaucoma in the primary-care screening context. It concluded that evidence was insufficient to determine the balance of benefits and harms of screening for primary open-angle glaucoma. This is an I statement: it is not evidence that glaucoma is harmless, a recommendation to avoid eye care, or guidance for someone with symptoms or a suspicious finding.

The Task Force found that tests can identify glaucoma and that pressure-lowering treatment improves intermediate outcomes, including pressure and measures of structural or field progression. The missing link was adequate direct evidence that a population-screening program improves patient-centered outcomes such as visual function and quality of life, including in higher-risk groups. Screening tests and specialty diagnostic tools are also not the same in every setting.

NEI separately states that detection in people at higher risk is best done through a comprehensive dilated eye exam and recommends one- to two-year examinations for specified higher-risk groups. This is risk-based case-finding and professional guidance. It can coexist with the USPSTF conclusion that universal primary-care screening evidence remains insufficient.

Avoid saying “everyone needs glaucoma screening” or, at the other extreme, “screening does not work.” A more accurate message is: discuss your personal risk and an appropriate comprehensive-exam schedule, and investigate symptoms or abnormal findings rather than waiting for a population recommendation.

What landmark trials added#

The NEI-funded Early Manifest Glaucoma Trial randomized people with newly diagnosed early open-angle glaucoma to immediate pressure-lowering treatment or no/delayed treatment. The trial showed that lowering pressure slowed progression for many participants, while progression rates varied. That supports treatment after diagnosis without implying that every person progresses identically.

The Ocular Hypertension Treatment Study enrolled people with elevated pressure but no glaucoma damage. Pressure-lowering therapy reduced the development of glaucoma during the original trial, but extended follow-up showed that many participants did not develop vision loss and that baseline risk differed. NEI's 2021 summary emphasizes that not every person with elevated pressure needs the same immediate treatment.

Together, these studies support risk stratification. The absolute benefit of intervention is larger when untreated risk is larger. Age, expected lifetime, and pressure all enter the decision. So do corneal thickness, nerve appearance, and field status. So do treatment burden, side effects, cost, and patient preference.

Treatment lowers risk; monitoring tests whether it is enough#

Current treatment aims to lower intraocular pressure using prescription eye medicines, laser procedures, or surgery. The choice depends on glaucoma type and stage, starting pressure, and likely adherence. It depends on other eye or medical conditions, prior treatment, and risk tolerance. It depends on access and preference. NICE's guideline includes diagnosis, case-finding, initial treatment, reassessment, and escalation pathways; local practice and regulatory approvals may differ.

Pressure lowering cannot restore established optic-nerve loss. It can reduce the chance or rate of further progression. A “target pressure” is therefore an individualized working estimate, not a permanent universal number. If fields or structure worsen despite reaching it, the target and treatment plan may need revision. If testing is stable, that evidence should be interpreted over an adequate interval and with test reliability in mind.

For eye medicines, technique matters. A bottle can be difficult to aim, schedules can be burdensome, and local or systemic effects may occur. Tell your clinician about missed doses, cost, and dexterity. Mention pregnancy, lung or heart conditions, and other medicines. Do not double, stop, or substitute treatment without guidance. Ask for a demonstration and a written plan.

Build a follow-up record#

Glaucoma care is longitudinal. Keep your diagnosis or risk category, the treated eye, the medicine list, prior laser or surgery, the target pressure if one is used, and the date of the next pressure, field, imaging, or dilated exam. Ask whether a change represents true progression, a test artifact, or uncertainty requiring repetition.

Seek urgent care for the acute angle-closure symptom cluster. Gradual peripheral loss, a new abnormal test, or family history deserves timely assessment but is not automatically an emergency. The vision-protection primer and cataract guide explain overlapping examination and aging issues.

Glaucoma deserves attention precisely because open-angle disease can begin without symptoms. Attention should be disciplined, not alarmist: assess your individual risk, use a comprehensive examination rather than a pressure number alone, read the population-screening evidence accurately, and monitor whether treatment is protecting your optic nerve over time.